Featured Story | By Gabrielle Masson New research shows a one-two hit from an experimental vaccine combo is significantly more effective at fighting off treatment-resistant cancers in animal models than either approach by itself—and the Department Defense is throwing down money to move the science into the clinic. read more |
| |
|---|
|
Top Stories By Angus Liu Inhibiting a protein could boost the efficacy of CAR-T cells by letting newly activated T cells preferentially differentiate toward long-lasting memory T cells rather than the short-living effector cells, scientists at St. Jude Children’s Research Hospital have shown. read more By Gabrielle Masson To help crack Alzheimer's disease, researchers are looking to a North Star—or, more accurately, a star-shaped cell in the brain that could play a role in progression of the neurodegenerative disease. read more By James Waldron Leukemia is notorious for being very aggressive and hard to eradicate from the body. The culprits are leukemic stem cells—known as “seed” cells—that drive resistance to chemotherapy and can trigger a relapse of the cancer. read more By Teresa Carey This week on "The Top Line," we discuss why scientists say we need an Alzheimer's moonshot. We also talk about a controversial take on diversity during a panel at the BIO conference. Plus, we'll hear award-winning ads that tug at our heartstrings. read more By Kevin Dunleavy,Fraiser Kansteiner,Emmy Lucas,Noah Higgins-Dunn A new COVID-19 variant, the omicron variant, could soon surge, the World Health Organization said. Those who received the Johnson & Johnson vaccine are often opting for other vaccines as a booster. Plus more. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In a year in which biopharma revenues increased dramatically, especially among companies that brought COVID-19 products to the market, many firms laid out eye-popping pay packages for their chief executives. Bookending this year's list are longtime CEOs who retired from powerhouse U.S. companies during the year—No. 1 Alex Gorsky of Johnson & Johnson and No. 15 Ken Frazier of Merck. read more Resources Sponsored By: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored By: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Blue Matter, strategic consultants in the life sciences Medical Affairs plays a critical role in generating insights to inform strategic decisions, but that role is changing. This paper explores why, and how MA teams can stay ahead of the curve. Sponsored By: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
